Patients are at the beginning, middle, and heart of all we do.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on Central Nervous System (CNS) disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.
Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.
Our initial work is focused on Central Nervous System (CNS) disorders. We are proud to be partnering with Dr. Jeanne-Marie Lecomte and Prof. Jean-Charles Schwartz, co-founders of French company Bioprojet SCR (Bioprojet), to develop, register, and market the drug pitolisant, a selective histamine H3-receptor antagonist/inverse agonist for the potential treatment of adult narcolepsy. Currently, no H3-receptor antagonist/inverse agonist has been approved by the US Food & Drug Administration (FDA).
We believe there is tremendous potential in this receptor and we are both proud and excited to be a part of the prospective novel treatments it might offer.